Home > Insider Trading > Filing (0001209191-21-068410)

Filing Details

Accession Number:: 0001209191-21-068410
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-07 18:36:44
Reporting Period:: 2021-12-03

Accepted Time:: 2021-12-07 18:36:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808865	Iteos Therapeutics Inc.	ITOS	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1729505	Mpm Bioventures 2018, L.p.	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1818701	Mpm Bioventures 2018 Gp Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No
1818702	Mpm Bioventures 2018 Llc	C/O Mpm Capital 450 Kendall Street Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-12-03	17,569	$34.68	2,917,732	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-03	2,419	$35.44	2,915,313	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-03	179	$36.26	2,915,134	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-06	8,469	$32.35	2,906,665	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-06	1,171	$33.57	2,905,494	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-06	508	$34.08	2,904,986	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-06	60	$35.04	2,904,926	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-07	17,962	$33.15	2,886,964	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2021-12-07	1,494	$34.11	2,885,470	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
The shares were sold as follows: 10,467 by MPM BioVentures 2014, L.P. ("BV 2014"), 359 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 6,612 by MPM BioVentures 2018, L.P. ("BV 2018") and 131 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.15 to $35.135 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,651,193 by BV 2014, 97,289 by, 56,834 by AM BV2014, 1,042,857 by BV 2018, 48,966 by BV 2018(B) and 20,593 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 1,441 by BV 2014, 50 by AM BV2014, 910 by BV 2018 and 18 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.15 to $36.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,649,752 by BV 2014, 97,289 by BV 2014(B), 56,784 by AM BV2014, 1,041,947 by BV 2018, 48,966 by BV 2018(B) and 20,575 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 107 by BV 2014, 4 by AM BV2014, 67 by BV 2018 and 1 by AM BV2018.
The shares are held as follows: 1,649,645 by BV 2014, 97,289 by BV 2014(B), 56,780 by AM BV2014, 1,041,880 by BV 2018, 48,966 by BV 2018(B) and 20,574 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 5,046 by BV 2014, 173 by AM BV2014, 3,187 by BV 2018 and 63 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.98 to $32.975 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,644,599 by BV 2014, 97,289 by BV 2014(B), 56,607 by AM BV2014, 1,038,693 by BV 2018, 48,966 by BV 2018(B) and 20,511 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 698 by BV 2014, 24 by AM BV2014, 441 by BV 2018 and 8 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.99 to $33.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,643,901 by BV 2014, 97,289 by BV 2014(B), 56,583 by AM BV2014, 1,038,252 by BV 2018, 48,966 by BV 2018(B) and 20,503 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 303 by BV 2014, 10 by AM BV2014, 191 by BV 2018 and 4 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.125 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,643,598 by BV 2014, 97,289 by BV 2014(B), 56,573 by AM BV2014, 1,038,061 by BV 2018, 48,966 by BV 2018(B) and 20,499 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 35 by BV 2014, 2 by AM BV2014, 22 by BV 2018 and 1 by AM BV2018.
The shares are held as follows: 1,643,563 by BV 2014, 97,289 by BV 2014(B), 56,571 by AM BV2014, 1,038,039 by BV 2018, 48,966 by BV 2018(B) and 20,498 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 10,701 by BV 2014, 368 by AM BV2014, 6,759 by BV 2018 and 134 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,632,862 by BV 2014, 97,289 by BV 2014(B), 56,203 by AM BV2014, 1,031,280 by BV 2018, 48,966 by BV 2018(B) and 20,364 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
The shares were sold as follows: 890 by BV 2014, 31 by AM BV2014, 562 by BV 2018 and 11 by AM BV2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.875 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held as follows: 1,631,972 by BV 2014, 97,289 by BV 2014(B), 56,172 by AM BV2014, 1,030,718 by BV 2018, 48,966 by BV 2018(B) and 20,353 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.